Lisa is a creative and seasoned litigator with a national practice focused on complex commercial, product liability, class action, toxic tort, environmental and premises liability cases throughout the country.
Leader of the Product Liability and Mass Tort Litigation Practice Team, co-leader of the Life Sciences and Health Effects Team and co-leader of the Class Action Practice Team, Lisa plays an active role in leading litigation at Phillips Lytle. In addition, she sat as member of the firm’s Governing Committee and participates as a vital member of the firm’s Strategic Planning Committee.
Lisa has decades of experience in litigating high-stakes product liability, toxic tort and environmental cases, often in multijurisdiction and class action settings. She advises companies on regulatory approval and compliance, product labeling and risk management. She is well equipped in handling complex litigation across multiple jurisdictions, with a focus on the defense of pharmaceutical, chemical and other product liability cases, as well as environmental claims.
Lisa’s practice also includes representing research hospitals, hospital systems and emerging medical technology companies. From her days as a biology major in college to her many years serving as national science counsel to global pharmaceutical companies, she has a decades-long focus on how science and scientific innovation can improve people’s lives. She currently serves on the board of directors for LifeSciencesNY.
For every client, Lisa believes in getting to the right result as quickly and cost-effectively as possible in order to save time, money and reputations. She deploys early and aggressive case assessment to plot out the most efficient paths to case resolution. Lisa understands that a key to success in any complex case is understanding the industry and how the litigation impacts the client.
Lisa is a mentor to others on her team, guiding their litigation strategy choices and imparting the values of client service and responsiveness that are the hallmarks of her practice.
Lisa is a dedicated advocate for women in the law, and deeply committed to charitable and pro bono work, including having represented migrant workers, AIDS patients and many other groups during her 27 years in the legal community. She also serves as vice president of The Pink Pillow Project, Inc., a breast cancer charity she co-founded.
Co-Author, “Understanding Cybersecurity Trends and the New NYSDOH Hospital Regulations,” Rochester Business Journal, January 2025
Co-Author, “Navigating Decentralized Clinical Trials With FSA’s Guidance,” Law360, November 2024
Co-Author, “What’s Next for MDMA? Clinicians, Researchers and Congressional Lawmakers Urge FDA to Approve MDMA for PTSD Despite a Negative Vote by FDA’s Advisory Committee” New York Law Journal, August 2024
Co-Author, “Major Milestone for Psychedelic-Assisted Therapy: Lykos Therapeutics Submits New Drug Application to the FDA for MDMA-Assisted Therapy for PTSD,” New York Law Journal, January 2024
Co-Author, “Amended Federal Rule 702 and Expert Admissibility: A Rule That Hit the Ground Running,” The National Law Review, December 2023
Co-Author, “FDA Draft Guidance on Clinical Trials for Psychedelics: A Closer Look,” Microdose.buzz, July 2023
Co-Author, “FDA Issues Draft Guidance on Diversity and Inclusion in Clinical Trials,” National Law Review, August 2022
Co-Author, “Everyday Epidemiology: How the Pandemic Brought Science to the Forefront of Public Consciousness,” Buffalo Business First, March 2022
Co-Author, “Cannabis Forethought: Labeling, Warnings and Risk Mitigation,” Buffalo Business First, February 2022
Co-Author, “How Medical Device Cos. Can Limit Enforcement, Legal Risks,” Law360, December 2021
Co-Author, “Baby Food Contamination Cases Face Class Action Hurdles,” Law360, June 2021
Co-Author, “Freedom to Innovate: Lessons From the COVID-19 Pandemic,” Buffalo Business First, March 2021
Want to Know More?
Receive firm communications, legal news and industry alerts delivered to your inbox.
